Human antibodies against eotaxin and their use

US10577413B2 · kind B2 · utility

Assignee

• MedImmune Limited · US

Inventors

• Tristan Vaughan · Cambridge, GB
• Alison J. Wilton · Cambridge, GB
• Stephen J. Smith · Los Gatos, US
• Sarah Helen Main · Royston, GB

Key dates

• Filing date: Feb 3, 2016
• Grant date: Mar 3, 2020
• Expiry date: Sep 13, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-213/-213 VH and/or VL domains especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members and their use in methods of inhibiting or neutralising eotaxin, including methods of treatment or the human or animal body by therapy.